Phase 2 N=33 Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Lymphoma
Primary: Response to Treatment — 0; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Phase 2 N=24 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Recurrent Mycosis Fungoides and Sezary Syndrome · Refractory Mycosis Fungoides and Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Objective Response Rate (ORR), Defined as a Confirmed Partial Response (PR) or Complete Response (CR) Using Global Assessment Standard Response Criteria for Mycosis…
Phase 2 N=9 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Mycosis Fungoides · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Primary: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle (Cutaneous Complete Response [CR], Cutaneous 90 Response [CR90] or Cutaneous Partial Response…
Phase 2 N=36 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Non-Hodgkin Lymphoma (NHL) · Cutaneous Lymphoma · Cutaneous T-cell Lymphoma (CTCL)
Primary: Overall Response Rate (ORR) — 70; 56; 79; 100 percentage
Phase 2 N=4 Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides
Lymphoma
Primary: Objective Response Rate — .25 proportion of participants
Phase 2 N=1 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Phase 2 N=28 Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Metastatic Myxoid Liposarcoma · Metastatic Round Cell Liposarcoma · Metastatic Synovial Sarcoma
Primary: Overall Response Rate (ORR) — 6; 0 Participants
Phase 2 N=38 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Phase 3 N=169 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Phase 1 N=6 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Adult T-Cell Lymphoma/Leukemia · Sezary Syndrome · Mycosis Fungoides
Primary: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin 15 (IL-15) (rhIL-15) — 2 mcg/kg/day
Phase 2 N=13 Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Phase 2 N=260 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Mycosis Fungoides
Primary: Ratio of Response Rates Based on CAILS — 76; 62 percentage of participants
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Phase 3 N=372 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Cutaneous T-Cell Lymphoma
Primary: Progression Free Survival — 55.3; 28.8; 38.3; 15.3 percentage of subjects
Phase 1 N=10 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
Phase 2 N=5 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Phase 1 N=20 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
N/A N=6 VircapSeq Virus Detection in Sézary Syndrome
Lymphoma, T-Cell, Cutaneous · Sézary Syndrome
Primary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
N/A N=298 Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Mycosis Fungoides
Primary: Treatment Responders Using Body Surface Area (BSA) at 12 Months — 44 Participants
Phase 3 N=21 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Primary: Lead-In Part: Number of Participants With Dose-limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03…
Phase 2 N=33 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Phase 2 N=108 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Phase 2 N=25 A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Among Mycosis Fungoides (MF) and Sezary Syndrome (SS) Participants (Response…
Phase 2 N=9 Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma · Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Number of Patients With Grade 3 or Above Toxicities — 9 Participants